创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

洪浩. 放射性核素偶联药物研发的优势与挑战[J]. 药学进展, 2023, 47(5): 321-323. DOI: 10.20053/j.issn1001-5094.2023.05.001
引用本文: 洪浩. 放射性核素偶联药物研发的优势与挑战[J]. 药学进展, 2023, 47(5): 321-323. DOI: 10.20053/j.issn1001-5094.2023.05.001
HONG Hao. Advantages and Challenges of Radionuclide Coupled Drugs Development[J]. Progress in Pharmaceutical Sciences, 2023, 47(5): 321-323. DOI: 10.20053/j.issn1001-5094.2023.05.001
Citation: HONG Hao. Advantages and Challenges of Radionuclide Coupled Drugs Development[J]. Progress in Pharmaceutical Sciences, 2023, 47(5): 321-323. DOI: 10.20053/j.issn1001-5094.2023.05.001

放射性核素偶联药物研发的优势与挑战

Advantages and Challenges of Radionuclide Coupled Drugs Development

/

返回文章
返回